Concurrent NRAS and ASXL1 mutations associate with poor prognosis in CMML. (A) Percentages of CMML patients with NRAS mutation in patients with MT or WT ASXL1 are shown. P value was determined using the χ² test. (B) Overall survival and leukemia-free survival of CMML patients stratified on the basis of ASXL1 and NRAS mutation status. P values were determined using the log-rank test.